Top

Published in:

01-04-2019 | Original Article

Strong antigen-specific T-cell immunity induced by a recombinant human TERT measles virus vaccine and amplified by a DNA/viral vector prime boost in IFNAR/CD46 mice

Authors: Elodie Pliquet, Claude Ruffie, Marie Escande, Jessie Thalmensi, Valérie Najburg, Chantal Combredet, Thomas Bestetti, Marion Julithe, Christelle Liard, Thierry Huet, Simon Wain-Hobson, Frédéric Tangy, Pierre Langlade-Demoyen

Published in: Cancer Immunology, Immunotherapy | Issue 4/2019

Abstract

Cancer immunotherapy is seeing an increasing focus on vaccination with tumor-associated antigens (TAAs). Human telomerase (hTERT) is a TAA expressed by most tumors to overcome telomere shortening. Tolerance to hTERT can be easily broken both naturally and experimentally and hTERT DNA vaccine candidates have been introduced in clinical trials. DNA prime/boost strategies have been widely developed to immunize efficiently against infectious diseases. We explored the use of a recombinant measles virus (MV) hTERT vector to boost DNA priming as recombinant live attenuated measles virus has an impressive safety and efficacy record. Here, we show that a MV-TERT vector can rapidly and strongly boost DNA hTERT priming in MV susceptible IFNAR/CD46 mouse models. The cellular immune responses were Th1 polarized. No humoral responses were elicited. The 4 kb hTERT transgene did not impact MV replication or induction of cell-mediated responses. These findings validate the MV-TERT vector to boost cell-mediated responses following DNA priming in humans.

Eggermont AMM, Kroemer G, Zitvogel L (2013) Immunotherapy and the concept of a clinical cure. Eur J Cancer 49(14):2965–2967. https://doi.org/10.1016/j.ejca.2013.06.019 CrossRefPubMed

Bluestone JA, Small EJ (2012) The future of cancer treatment: will it include immunotherapy? Cancer Cell 22(1):7–8. https://doi.org/10.1016/j.ccr.2012.06.009 CrossRefPubMed

Draper SJ, Heeney JL (2010) Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 8(1):62–73. https://doi.org/10.1038/nrmicro2240 CrossRefPubMed

Bonnet MC, Tartaglia J, Verdier F, Kourilsky P, Lindberg A, Klein M, Moingeon P (2000) Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol Lett 74(1):11–25. https://doi.org/10.1016/S0165-2478(00)00244-3 CrossRefPubMed

Larocca C, Schlom J (2011) Viral vector-based therapeutic cancer vaccines. Cancer J 17(5):359–371. https://doi.org/10.1097/PPO.0b013e3182325e63 CrossRefPubMedPubMedCentral

Moss WJ, Griffin DE (2012) Measles. Lancet 379(9811):153–164. https://doi.org/10.1016/S0140-6736(10)62352-5 CrossRefPubMed

Hilleman MR (2001) Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. Vaccine 20(5–6):651–665. https://doi.org/10.1016/S0264-410X(01)00384-X CrossRefPubMed

Guillerme J-B, Gregoire M, Tangy F, Fonteneau J-F (2013) Antitumor virotherapy by attenuated measles virus (MV). Biology 2(2):587. https://doi.org/10.3390/biology2020587 CrossRefPubMedPubMedCentral

Amanna IJ, Carlson NE, Slifka MK (2007) Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357(19):1903–1915. https://doi.org/10.1056/NEJMoa066092 CrossRefPubMed

10.

Zuniga A, Wang Z, Liniger M, Hangartner L, Caballero M, Pavlovic J, Wild P, Viret JF, Glueck R, Billeter MA, Naim HY (2007) Attenuated measles virus as a vaccine vector. Vaccine 25(16):2974–2983. https://doi.org/10.1016/j.vaccine.2007.01.064 CrossRefPubMedPubMedCentral

11.

Brandler S, Tangy F (2008) Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines. Comp Immunol Microbiol Infect Dis 31(2–3):271–291. https://doi.org/10.1016/j.cimid.2007.07.012 CrossRefPubMed

12.

Ramsauer K, Schwameis M, Firbas C, Mullner M, Putnak RJ, Thomas SJ, Despres P, Tauber E, Jilma B, Tangy F (2015) Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis 15(5):519–527. https://doi.org/10.1016/S1473-3099(15)70043-5 CrossRefPubMed

13.

Knuchel MC, Marty RR, Morin TN, Ilter O, Zuniga A, Naim HY (2013) Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector. Hum Vaccines Immunother 9(3):599–606. https://doi.org/10.4161/hv.23241 CrossRef

14.

Russell SJ, Peng KW (2009) Measles virus for cancer therapy. Curr Top Microbiol Immunol 330:213–241PubMedPubMedCentral

15.

Msaouel P, Iankov ID, Allen C, Morris JC, von Messling V, Cattaneo R, Koutsilieris M, Russell SJ, Galanis E (2009) Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate 69(1):82–91. https://doi.org/10.1002/pros.20857 CrossRefPubMedPubMedCentral

16.

Zanetti M (2017) A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nat Rev Clin Oncol 14(2):115–128. https://doi.org/10.1038/nrclinonc.2016.67 CrossRefPubMed

17.

Collins K, Mitchell JR (2002) Telomerase in the human organism. Oncogene 21(4):564–579. https://doi.org/10.1038/sj.onc.1205083 CrossRefPubMed

18.

Low KC, Tergaonkar V (2013) Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem Sci 38(9):426–434. https://doi.org/10.1016/j.tibs.2013.07.001 CrossRefPubMed

19.

Shay JW, Bacchetti S (1997) A survey of telomerase activity in human cancer. Eur J Cancer 33(5):787–791. https://doi.org/10.1016/S0959-8049(97)00062-2 CrossRefPubMed

20.

Zhu CQ, Cutz JC, Liu N, Lau D, Shepherd FA, Squire JA, Tsao MS (2006) Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer. Br J Cancer 94(10):1452–1459. https://doi.org/10.1038/sj.bjc.6603110 CrossRefPubMedPubMedCentral

21.

Lü M-H, Deng J-Q, Cao Y-L, Fang D-C, Zhang YAO, Yang S-M (2012) Prognostic role of telomerase activity in gastric adenocarcinoma: a meta-analysis. Exp Ther Med 3(4):728–734. https://doi.org/10.3892/etm.2012.471 CrossRefPubMedPubMedCentral

22.

Karanikas V, Zamanakou M, Soukou F, Kerenidi T, Gourgoulianis KI, Germenis AE (2010) Naturally occurring tumor-specific CD8+ T-cell precursors in individuals with and without cancer. Immunol Cell Biol 88(5):575–585. https://doi.org/10.1038/icb.2010.8 CrossRefPubMed

23.

Thalmensi J, Pliquet E, Liard C, Escande M, Bestetti T, Julithe M, Kostrzak A, Pailhes-Jimenez A-S, Bourges E, Loustau M, Caumartin J, Lachgar A, Huet T, Wain-Hobson S, Langlade-Demoyen P (2016) Anticancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T cell immune response. Oncoimmunology 5(3):e1083670. https://doi.org/10.1080/2162402X.2015.1083670 CrossRefPubMed

24.

Rice J, Ottensmeier CH, Stevenson FK (2008) DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 8(2):108–120. https://doi.org/10.1038/nrc2326 CrossRefPubMed

25.

Brown SA, Surman SL, Sealy R, Jones BG, Slobod KS, Branum K, Lockey TD, Howlett N, Freiden P, Flynn P, Hurwitz JL (2010) Heterologous prime-boost HIV-1 vaccination regimens in pre-clinical and clinical trials. Viruses 2(2):435–467. https://doi.org/10.3390/v2020435 CrossRefPubMedPubMedCentral

26.

Hallengärd D, Lum F-M, Kümmerer BM, Lulla A, Lulla V, García-Arriaza J, Fazakerley JK, Roques P, Le Grand R, Merits A, Ng LFP, Esteban M, Liljeström P (2014) Prime-boost immunization strategies against chikungunya virus. J Virol 88(22):13333–13343. https://doi.org/10.1128/JVI.01926-14 CrossRefPubMedPubMedCentral

27.

Smith CL, Dunbar PR, Mirza F, Palmowski MJ, Shepherd D, Gilbert SC, Coulie P, Schneider J, Hoffman E, Hawkins R, Harris AL, Cerundolo V (2005) Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 113(2):259–266. https://doi.org/10.1002/ijc.20569 CrossRefPubMed

28.

Kim SB, Ahn JH, Kim J, Jung KH (2015) A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer. Mol Ther Methods Clin Dev 2:15031. https://doi.org/10.1038/mtm.2015.31 CrossRefPubMedPubMedCentral

29.

Drosopoulos WC, Prasad VR (2007) The active site residue Valine 867 in human telomerase reverse transcriptase influences nucleotide incorporation and fidelity. Nucleic Acids Res 35(4):1155–1168. https://doi.org/10.1093/nar/gkm002 CrossRefPubMedPubMedCentral

30.

Yang Y, Chen Y, Zhang C, Huang H, Weissman SM (2002) Nucleolar localization of hTERT protein is associated with telomerase function. Exp Cell Res 277(2):201–209. https://doi.org/10.1006/excr.2002.5541 CrossRefPubMed

31.

Bachmair A, Finley D, Varshavsky A (1986) In vivo half-life of a protein is a function of its amino-terminal residue. Science 234(4773):179–186. https://doi.org/10.1126/science.3018930 CrossRef

32.

Bankamp B, Takeda M, Zhang Y, Xu W, Rota PA (2011) Genetic Characterization of measles vaccine strains. J Infect Dis 204(suppl 1):S533–S548. https://doi.org/10.1093/infdis/jir097 CrossRefPubMed

33.

Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, Dotsch C, Christiansen G, Billeter MA (1995) Rescue of measles viruses from cloned DNA. EMBO J 14(23):5773–5784CrossRefPubMedPubMedCentral

34.

Combredet C, Labrousse V, Mollet L, Lorin C, Delebecque F, Hurtrel B, McClure H, Feinberg MB, Brahic M, Tangy F (2003) A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol 77(21):11546–11554. https://doi.org/10.1128/JVI.77.21.11546-11554.2003 CrossRefPubMedPubMedCentral

35.

Lorin C, Delebecque F, Labrousse V, Da Silva L, Lemonnier F, Brahic M, Tangy F (2005) A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes. Vaccine 23(36):4463–4472. https://doi.org/10.1016/j.vaccine.2005.04.024 CrossRefPubMed

36.

Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B (1997) HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185(12):2043–2051. https://doi.org/10.1084/jem.185.12.2043 CrossRefPubMedPubMedCentral

37.

Hernandez J, Garcia-Pons F, Lone YC, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M (2002) Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci USA 99(19):12275–12280. https://doi.org/10.1073/pnas.182418399 CrossRefPubMed

38.

Dosset M, Godet Y, Vauchy C, Beziaud L, Lone YC, Sedlik C, Liard C, Levionnois E, Clerc B, Sandoval F, Daguindau E, Wain-Hobson S, Tartour E, Langlade-Demoyen P, Borg C, Adotevi O (2012) Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor. Clin Cancer Res Off J Am Assoc Cancer Res 18(22):6284–6295. https://doi.org/10.1158/1078-0432.CCR-12-0896 CrossRef

39.

Komarova AV, Combredet C, Meyniel-Schicklin L, Chapelle M, Caignard G, Camadro JM, Lotteau V, Vidalain PO, Tangy F (2011) Proteomic analysis of virus–host interactions in an infectious context using recombinant viruses. Mol Cell Proteom 10(12):M110 007443. https://doi.org/10.1074/mcp.M110.007443 CrossRef

40.

Durward M, Harms J, Splitter G (2010) Antigen specific killing assay using CFSE labeled target cells. J Vis Exp. https://doi.org/10.3791/2250 CrossRefPubMedPubMedCentral

41.

Lu S (2009) Heterologous prime-boost vaccination. Curr opin immunol 21(3):346–351.https://doi.org/10.1016/j.coi.2009.05.016 CrossRefPubMedPubMedCentral

42.

Ishii KJ, Kawagoe T, Koyama S, Matsui K, Kumar H, Kawai T, Uematsu S, Takeuchi O, Takeshita F, Coban C, Akira S (2008) TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 451(7179):725–729. https://doi.org/10.1038/nature06537 CrossRefPubMed

43.

Coban C, Kobiyama K, Aoshi T, Takeshita F, Horii T, Akira S, Ishii KJ (2011) Novel strategies to improve DNA vaccine immunogenicity. Curr Gene Ther 11(6):479–484. https://doi.org/10.2174/156652311798192815 CrossRefPubMed

44.

Tasaki T, Sriram SM, Park KS, Kwon YT (2012) The N-end rule pathway. Annu Rev Biochem 81:261–289. https://doi.org/10.1146/annurev-biochem-051710-093308 CrossRefPubMedPubMedCentral

45.

Mrkic B, Pavlovic J, Rulicke T, Volpe P, Buchholz CJ, Hourcade D, Atkinson JP, Aguzzi A, Cattaneo R (1998) Measles virus spread and pathogenesis in genetically modified mice. J Virol 72(9):7420–7427PubMedPubMedCentral

46.

Ludlow M, de Vries RD, Lemon K, McQuaid S, Millar E, van Amerongen G, Yuksel S, Verburgh RJ, Osterhaus AD, de Swart RL, Duprex WP (2013) Infection of lymphoid tissues in the macaque upper respiratory tract contributes to the emergence of transmissible measles virus. J Gen Virol 94(Pt 9):1933–1944. https://doi.org/10.1099/vir.0.054650-0 CrossRefPubMed

47.

Woodland DL (2004) Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 25(2):98–104. https://doi.org/10.1016/j.it.2003.11.009 CrossRefPubMed

48.

Palucka K, Ueno H, Banchereau J (2011) Recent developments in cancer vaccines. J Immunol 186(3):1325–1331. https://doi.org/10.4049/jimmunol.0902539 CrossRefPubMedPubMedCentral

Title: Strong antigen-specific T-cell immunity induced by a recombinant human TERT measles virus vaccine and amplified by a DNA/viral vector prime boost in IFNAR/CD46 mice
Authors: Elodie Pliquet
Claude Ruffie
Marie Escande
Jessie Thalmensi
Valérie Najburg
Chantal Combredet
Thomas Bestetti
Marion Julithe
Christelle Liard
Thierry Huet
Simon Wain-Hobson
Frédéric Tangy
Pierre Langlade-Demoyen
Publication date: 01-04-2019
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 4/2019
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-018-2272-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2019

The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma

MDSCs in infectious diseases: regulation, roles, and readjustment

A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma

Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates

MDSC and beyond: a symposium-in-writing on myeloid cells with immunoregulatory activity by members of the Mye-EUNITER network

Interactions among myeloid regulatory cells in cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer